Patents by Inventor Michel Nussenzweig

Michel Nussenzweig has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250144197
    Abstract: This disclosure provides HIV immunogens and use thereof for generating an immune response in a subject. Also disclosed is a method of isolating anti-HIV antibodies and use thereof. This disclosure further provides a method for treating or preventing a human immunodeficiency type 1 (HIV-1) infection in a subject using the disclosed HIV immunogens and/or antibodies.
    Type: Application
    Filed: January 9, 2025
    Publication date: May 8, 2025
    Inventors: Michel Nussenzweig, Pamela J. Bjorkman, Amelia Escolano, Harry Gristick
  • Publication number: 20250115661
    Abstract: The present invention relates to broadly neutralizing anti-HIV-1 antibodies and isolated antigens. Also disclosed are related methods and compositions.
    Type: Application
    Filed: October 10, 2024
    Publication date: April 10, 2025
    Applicants: The Rockefeller University, California Institute of Technology
    Inventors: Michel Nussenzweig, Pamela J. Bjorkman, Louise Scharf, Johannes Scheid
  • Patent number: 12239698
    Abstract: This disclosure provides HIV immunogens and use thereof for generating an immune response in a subject. Also disclosed is a method of isolating anti-HIV antibodies and use thereof. This disclosure further provides a method for treating or preventing a human immunodeficiency type 1 (HIV-1) infection in a subject using the disclosed HIV immunogens and/or antibodies.
    Type: Grant
    Filed: November 27, 2019
    Date of Patent: March 4, 2025
    Assignees: The Rockefeller University, California Institute of Technology
    Inventors: Michel Nussenzweig, Pamela J. Bjorkman, Amelia Escolano, Harry Gristick
  • Patent number: 12234278
    Abstract: The present invention relates to methods and agents for preventing the establishment of HIV-1 latent reservoirs or for reducing the size of the reservoirs. Specifically, the disclosure provides methods and agents for preventing the establishment of HIV-1 latent reservoirs or for reducing the size of the reservoirs, the methods comprising administering to the subject a therapeutically effective amount of an isolated anti-HIV antibody, and administering to the subject two or more viral transcription inducers in effective amounts to induce transcription of an HIV provirus in the cells. Further provided are antibodies and viral transcription inducers used in the methods.
    Type: Grant
    Filed: May 28, 2020
    Date of Patent: February 25, 2025
    Assignee: The Rockefeller University
    Inventors: Michel Nussenzweig, Ariel Halper-Stromberg, Ching-Lan Lu
  • Patent number: 12173052
    Abstract: Embodiments of the present invention are directed to compositions and methods for anti-HIV (anti-CD4 binding site) broadly neutralizing antibodies having improved potency and breadth for neutralizing a range of HIV strains. Combinations of broadly neutralizing antibodies can also improve potency over a single antibody composition.
    Type: Grant
    Filed: October 13, 2021
    Date of Patent: December 24, 2024
    Assignees: The Rockefeller University, California Institute of Technology
    Inventors: Ron Diskin, Anthony P. West, Michel Nussenzweig, Pamela J. Bjorkman
  • Patent number: 12071470
    Abstract: The invention provides broadly neutralizing antibodies directed to epitopes of Human Immunodeficiency Virus, or HIV. The invention further provides compositions containing HIV antibodies used for prophylaxis, and methods for diagnosis and treatment of HIV infection.
    Type: Grant
    Filed: February 22, 2023
    Date of Patent: August 27, 2024
    Assignees: The Rockefeller University, California Institute of Technology
    Inventors: Johannes Scheid, Michel Nussenzweig, Pamela J. Bjorkman, Ron Diskin
  • Patent number: 12060411
    Abstract: This disclosure provides novel neutralizing anti-SARS-CoV-2 antibodies or antigen-binding fragments thereof. The disclosed anti-SARS-CoV-2 antibodies constitute a novel therapeutic strategy in protection from SARS-CoV-2 infections.
    Type: Grant
    Filed: January 13, 2022
    Date of Patent: August 13, 2024
    Assignee: The Rockefeller University
    Inventors: Michel Nussenzweig, Zijun Wang
  • Publication number: 20240262895
    Abstract: This invention relates to broadly neutralizing and potent anti-HIV-1 antibodies, kits, and methods of use thereof.
    Type: Application
    Filed: December 20, 2023
    Publication date: August 8, 2024
    Inventors: Michel Nussenzweig, Natalia T. Freund, Pamela J. Bjorkman, Louise Scharf
  • Patent number: 12054538
    Abstract: Embodiments of the present invention are directed to compositions and methods for anti-HIV (anti-CD4 binding site) potent VRC01-like (PVL) antibodies targeted to gp120 having an amino acid substitution at a residue in the anti-CD4 binding site PVL antibody that is equivalent to Phe43 in CD4, these antibodies having improved potency and breadth.
    Type: Grant
    Filed: October 13, 2022
    Date of Patent: August 6, 2024
    Assignees: California Institute of Technology, The Rockefeller University
    Inventors: Ron Diskin, Pamela J. Bjorkman, Michel Nussenzweig, Johannes Scheid
  • Publication number: 20240254206
    Abstract: The invention provides broadly neutralizing antibodies directed to epitopes of Human Immunodeficiency Virus, or HIV. The invention further provides compositions containing HIV antibodies used for prophylaxis, and methods for diagnosis and treatment of HIV infection.
    Type: Application
    Filed: March 6, 2024
    Publication date: August 1, 2024
    Inventors: Johannes Scheid, Michel Nussenzweig, Pamela J. Bjorkman, Ron Diskin
  • Publication number: 20240150439
    Abstract: This disclosure provides novel broadly neutralizing anti-SARS-CoV-2 antibodies or antigen-binding fragments thereof. The disclosed anti-SARS-CoV-2 antibodies constitute a novel therapeutic strategy in protection from SARS-CoV-2 infections.
    Type: Application
    Filed: April 24, 2023
    Publication date: May 9, 2024
    Applicant: The Rockefeller University
    Inventors: Michel Nussenzweig, Davide F. Robbiani
  • Patent number: 11919945
    Abstract: This disclosure provides novel broadly neutralizing anti-SARS-CoV-2 antibodies or antigen-binding fragments thereof. The disclosed anti-SARS-CoV-2 antibodies constitute a novel therapeutic strategy in protection against SARS-CoV-2 infections.
    Type: Grant
    Filed: November 4, 2021
    Date of Patent: March 5, 2024
    Assignee: The Rockefeller University
    Inventor: Michel Nussenzweig
  • Patent number: 11897940
    Abstract: This invention relates to broadly neutralizing and potent anti-HIV-1 antibodies, kits, and methods of use thereof.
    Type: Grant
    Filed: March 30, 2022
    Date of Patent: February 13, 2024
    Assignees: THE ROCKEFELLER UNIVERSITY, CALIFORNIA INSTITUTE OF TECHNOLOGY
    Inventors: Michel Nussenzweig, Natalia T. Freund, Pamela J. Bjorkman, Louise Scharf
  • Publication number: 20240002480
    Abstract: This disclosure provides novel broadly neutralizing anti-tick-borne encephalitis virus (TBEV) antibodies. The disclosed anti-TBEV antibodies represent a novel therapeutic strategy for preventing or treating diseases or infections caused by various tick-borne flaviviruses, including TBEV.
    Type: Application
    Filed: November 23, 2021
    Publication date: January 4, 2024
    Applicant: The Rockefeller University
    Inventors: Michel Nussenzweig, Davide F. Robbiani
  • Publication number: 20230365661
    Abstract: The invention provides broadly neutralizing antibodies directed to epitopes of Human Immunodeficiency Virus, or HIV. The invention further provides compositions containing HIV antibodies used for prophylaxis, and methods for diagnosis and treatment of HIV infection.
    Type: Application
    Filed: February 22, 2023
    Publication date: November 16, 2023
    Applicants: The Rockefeller University, California Institute of Technology
    Inventors: Johannes Scheid, Michel Nussenzweig, Pamela J. Bjorkman, Ron Diskin
  • Publication number: 20230279082
    Abstract: The present invention relates to anti-HIV antibodies. Also disclosed are related methods and compositions. HIV causes acquired immunodeficiency syndrome (AIDS), a condition in humans characterized by clinical features including wasting syndromes, central nervous system degeneration and profound immunosuppression that results in life-threatening opportunistic infections and malignancies. Since its discovery in 1981, HIV type 1 (HIV-1) has led to the death of at least 25 million people worldwide.
    Type: Application
    Filed: April 7, 2023
    Publication date: September 7, 2023
    Applicants: The Rockefeller University, California Institute of Technology
    Inventors: Hugo Mouquet, Michel Nussenzweig, Pamela J. Bjorkman, Louise Scharf
  • Publication number: 20230192823
    Abstract: Embodiments of the present invention are directed to compositions and methods for anti-HIV (anti-CD4 binding site) potent VRC01-like (PVL) antibodies targeted to gp120 having an amino acid substitution at a residue in the anti-CD4 binding site PVL antibody that is equivalent to Phe43 in CD4, these antibodies having improved potency and breadth.
    Type: Application
    Filed: October 13, 2022
    Publication date: June 22, 2023
    Inventors: Ron Diskin, Pamela J. Bjorkman, Michel Nussenzweig, Johannes Scheid
  • Publication number: 20230181636
    Abstract: This disclosure provides modified B cells which produce heterologous antibodies and co-express cargo proteins. The modified B cells may be stimulated by binding of a cognate antigen to the heterologous antibodies. The B cells may be reduced or eliminated by contacting the heterologous antibody with an anti-idiotypic antibody. Methods of making, and using the modified B cells for prophylaxis and therapy for a variety of conditions are provided. The B cells are modified at an IgH locus, an IgK locus, and combinations thereof. Modified B cells maintain allelic exclusion.
    Type: Application
    Filed: March 18, 2021
    Publication date: June 15, 2023
    Inventors: Harald HARTWEGER, Mila JANKOVIC, Michel NUSSENZWEIG
  • Patent number: 11649276
    Abstract: The present invention relates to anti-HIV antibodies. Also disclosed are related methods and compositions. HIV causes acquired immunodeficiency syndrome (AIDS), a condition in humans characterized by clinical features including wasting syndromes, central nervous system degeneration and profound immunosuppression that results in life-threatening opportunistic infections and malignancies. Since its discovery in 1981, HIV type 1 (HIV-1) has led to the death of at least 25 million people worldwide.
    Type: Grant
    Filed: September 9, 2021
    Date of Patent: May 16, 2023
    Assignees: The Rockefeller University, California Institute of Technology
    Inventors: Hugo Mouquet, Michel Nussenzweig, Pamela J. Bjorkman, Louise Scharf
  • Patent number: 11634477
    Abstract: This disclosure provides novel broadly neutralizing anti-SARS-CoV-2 antibodies or antigen-binding fragments thereof. The disclosed anti-SARS-CoV-2 antibodies constitute a novel therapeutic strategy in protection from SARS-CoV-2 infections.
    Type: Grant
    Filed: April 28, 2021
    Date of Patent: April 25, 2023
    Assignee: The Rockefeller University
    Inventors: Michel Nussenzweig, Davide F. Robbiani